期刊
TRANSFUSION MEDICINE AND HEMOTHERAPY
卷 43, 期 2, 页码 109-113出版社
KARGER
DOI: 10.1159/000444942
关键词
Mast cells; New targets; Anti-cancer therapy
Mast cells (MCs) are cells that originate in the bone marrow from pluripotent CD34+ hennatopoietic stem cells. Precursors of MCs migrate through the circulation to their target tissues, completing their maturation process into granulated cells under the influence of several microenvironnnent growth factors. The most important of these factors is the ligand for the c-Kit receptor (c-Kit-R)namely stem cell factor (SCF), secreted mainly by fibroblasts and endothelial cells (ECs). SCF also regulates developnnent, survival and de novo proliferation of MCs. It has already been demonstrated that gain-of-function mutations of gene c-Kit encoding c-Kit-R result in the developnnent of some tumors. Furthermore, MCs are able also to modulate both innate and adaptive immune response and to express the high-affinity IgE receptor following IgE activation. Among the other IgE-independent MC activation mechanisms, a wide variety of other surface receptors for cytokines, chennokines, innnnunoglobulins, and complement are also described. Interestingly, MCs can stimulate angiogenesis by releasing of several pro-angiogenic cytokines stored in their cytoplasm. Studies published in the last year suggest that angiogenesis stimulated by MCs may play an important role in tumor growth and progression. Here, we aim to focus several biological features of MCs and to sunnmarize new anti-cancer MC-targeted strategies with potential translation in human clinical trials. (C) 2016 S. Karger GmbH, Freiburg
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据